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Background and Purpose:

Hypertension adversely affects the kidney and is the

second leading cause of kidney failure. Overproduction of angiotensin II greatly con-
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tributes to the progression of hypertensive kidney disease. Angiotensin II has recently

3

anisms of STAT3 activation by angiotensin II and downstream functional conse-
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been shown to activate STAT3 in cardiovascular cells. However, the underlying mechquences in the kidneys are not fully understood.
Experimental Approach:
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C57BL/6 mice were treated with angiotensin II by subcu-

taneous infusion for 1 month to develop nephropathy. Mice were treated with either
adeno‐associated virus expressing STAT3 shRNA or STAT3 inhibitor, S3I‐201. Human
archival kidney samples from five patients with hypertension and five individuals
without hypertension were also examined. In vitro, STAT3 was blocked using siRNA
or STAT3 inhibitor S3I‐201 in the renal proximal tubular cell line, NRK52E, after
exposure to angiotensin II.
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Key Results:

Angiotensin II activated STAT3 in kidney epithelial cells through

engaging toll‐like receptor 4 (TLR4) and JAK2, which was independent of IL‐6/
gp130 and angiotensin AT1 receptors. Angiotensin II‐mediated STAT3 activation
increased fibrotic proteins and resulted in renal dysfunction. Both STAT3 inhibition
by the low MW compound S3I‐201 and TLR4 deficiency normalized renal fibrosis
and dysfunction caused by Ang II in mice, without affecting hypertension.

[Correction added on 6 January, after first
online publication: Funding Information has
been corrected in this current version.]

Conclusions and Implications:

Our study reveals a novel mechanism of STAT3

activation, induced by angiotensin II, in kidney tissues and highlights a translational
significance of a STAT3 inhibitor as potential therapeutic agent for hypertensive
kidney disease.

Abbreviations: AAV, adeno‐associated virus; Ang II, angiotensin II; MD2, myeloid differentiation protein 2; p‐STAT3, phosphorylated STAT3; RAS, renin‐angiotensin system
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I N T RO D U CT I O N
What is already known

Hypertension affects approximately a quarter of the world popula-

• Angiotensin II is a major contributor to hypertensive

tion and causes an estimated 7 million deaths each year (Fagard,

kidney disease.

2012). Prevalence of hypertension is expected to rise to 30% by

• STAT3 is involved in renal injuries induced by ischaemia/

2025 (Kearney et al., 2005). Hypertension adversely affects the kid-

reperfusion and diabetes.

neys and is one of the most common causes of kidney failure.
Hypertensive kidney disease is characterized by tubulointerstitial

What this study adds

fibrosis, inflammatory infiltration, loss of renal parenchyma and

• Inhibition of STAT3 normalized angiotensin II‐induced

tubular atrophy, and capillary and podocyte loss (Brenner, 2002;

renal fibrosis and dysfunction in mice.

Liu, 2006).

• Angiotensin II activates STAT3 in kidney epithelial cells

The renin‐angiotensin system (RAS) is important in blood pres-

through engaging TLR4 and JAK2.

sure control and the pathogenesis of hypertension‐associated organ
damage (Navar, Prieto, Satou, & Kobori, 2011). In this system, angiotensin II (Ang II) is the main effector molecule. Ang II primarily medi-

What is the clinical significance

ates its actions by activating angiotensin AT1 and AT2 receptors.

• STAT3 inhibition is a novel potential therapeutic strategy
for hypertensive kidney disease.

Treatment of patients with chronic kidney disease and persistent
proteinuria with the aldosterone antagonist, spironolactone, reduced
proteinuria after 4 weeks (Sekizawa et al., 2011). Clinical evidence
also shows reno‐protective effects of inhibiting the RAS in diabetic

In this study, we have tested the hypothesis that Ang II activates

patients with kidney failure (Viberti, Wheeldon, & MicroAlbuminuria

STAT3 through TLR4 in kidney epithelial cells and in kidney tissues

Reduction With, 2002). It is also being recognized now that many

of mice. We utilized renal epithelial cells to investigate the roles of

tissues have their own local RAS (Paul, Poyan Mehr, & Kreutz,

STAT3 and TLR4 in Ang II‐induced renal dysfunction, because

2006; Re, 2004). In particular, intrarenal Ang II is elevated in many

tubulointerstitial fibrosis, the downstream effect of epithelial dysfunc-

forms of hypertension, implying a role in the development of hyper-

tion and loss, is a characteristic feature of hypertensive kidney disease.

tension and the associated kidney injury (Navar, Harrison‐Bernard,

Furthermore, STAT3 activation in renal epithelial cells has been

Nishiyama, & Kobori, 2002). Ang II overexpression specifically in

shown to induce extracellular matrix proteins (Ni et al., 2014). Hence,

the kidneys has been shown to increase blood pressure and the

uncovering the mechanism by which Ang II induces epithelial dysfunc-

development of renal inflammation and fibrosis (Kobori et al.,

tion is important for the development of new therapeutic options. Our

2007). These studies illustrate an important role for Ang II in kidney

results show that Ang II causes rapid STAT3 activation via TLR4 and

disease.

JAK2, but independent of AT1 receptors in kidney epithelial cells.

Ang II is known to engage JAK and other non‐receptor TKs to elicit

Activation of STAT3, downstream of Ang II, increased the expression

intracellular signalling (Doan, Ali, & Bernstein, 2001; Marrero et al.,

of collagen and fibrogenic growth factors, causing renal fibrosis. We

1995). The JAK family of proteins are TKs and comprise four members

further show that both TLR4 deficiency and pharmacological inhibition

in mammals: JAK1, JAK2, JAK3, and tyrosine kinase 2 (Schindler &

of STAT3 effectively prevented Ang II‐induced kidney injury.

Darnell, 1995). When JAK is activated, signal transducer and activator
of transcription (STAT) proteins are recruited and phosphorylated.
Following phosphorylation and activation, STATs form homodimers

2

METHODS

|

or heterodimers that translocate to the nucleus and activate the transcription of target genes (Murray, 2007). The JAK/STAT signalling

2.1

|

Cell culture

pathway constitutes one of the primary regulatory pathways for cytokine expression (Schindler, 2002). Although Ang II has been docu-

Rat kidney proximal tubule epithelial line NRK‐52E was obtained from

mented to activate STAT in a number of cell types, the precise

American Type Culture Collection (Manassas, VA; Cat# CRL‐1571;

mechanisms involved in kidney cells are not fully clear. We have

RRID:CVCL_0468). NRK‐52E cells were used as they are easily cul-

recently shown that Ang II directly binds myeloid differentiation pro-

tured and allow many downstream assays to be conducted. NRK‐

tein 2 (MD2) to rapidly activate the toll‐like receptor 4 (TLR4; Han

52E cells also have an intact RAS (Alzayadneh & Chappell, 2015),

et al., 2017). Studies showing Ang II triggering TLR4 activation in the

which is critical to the objectives of this study. The cells were main-

kidney are also emerging (Biancardi, Bomfim, Reis, Al‐Gassimi, &

tained in DMEM (Gibco, Eggenstein, Germany) containing 1.5‐g·L−1

Nunes, 2017). Furthermore, Ang II has been reported to engage

sodium bicarbonate and 4.5‐g·L−1 glucose. The media was supple-

TLR4 to activate STAT3 in producing abdominal aortic aneurysms

mented with 5% FBS (Gibco, Grand Island, NY), 100 U·ml−1 of penicil-

upon Ang II infusion in mice (Qin et al., 2015). These studies raise

lin, and 100 mg·ml−1 of streptomycin. Where indicated, IL‐6 and Ang II

the intriguing possibility that Ang II engages TLR4 to activate STAT3

protein levels were measured in culture media, following all cell treat-

in the kidney, resulting in renal fibrosis.

ments and exposures, using commercial ELISA kits (Nanjing Jiancheng
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Bioengineering Institute, Jiangsu, China). Gene silencing in NRK‐52E

(b) AAV2‐NC‐treated mice with Ang II (AAV2‐NC + Ang II group,

was performed by transfecting cells with appropriate siRNAs using

n = 7); (c) AAV2‐shSTAT3‐treated mice that received PBS (AAV2‐

Lipofectamine (Invitrogen, Carlsbad, CA). Sequences of the siRNAs

shSTAT3, n = 7); and (d) AAV2‐shSTAT3‐treated mice with Ang II

used are provided in Table S2. Briefly, cells were plated at a density

(AAV2‐shSTAT3 + Ang II, n = 7).

of 5 × 104 and cultured for 24 hr. Target siRNA or non‐targeting con-

Animal treatment (b): Ten‐week‐old C57BL/6 mice (n = 21) were

trol siRNA were transfected at a final concentration of 50 pmol·ml−1

randomly allocated initially into two three groups: (a) WT mice were

using lipofectamine. Culture medium was replaced with fresh growth

subcutaneously injected with PBS (WT Ctrl group, n = 7), (b) WT mice

medium after 6 hr. Knockdown effectiveness was determined by

were challenged with Ang II (WT Ang II, n = 7), and (c) WT mice were

western blotting.

challenged with Ang II and treated with STAT3 inhibitor S3I‐201 (WT
Ang II + S3I‐201, n = 7). At the same time, 10‐week‐old TLR4−/− mice
with C57BL/6 background (n = 14) were randomized either to receive

2.2

|

Ang II‐induced kidney disease mouse model

daily injections of Ang II or vehicle: (d) TLR4−/− mice were subcutaneously injected with PBS (TLR4−/− Ctrl, n = 7), and (e) TLR4−/− mice

All animal care and experimental procedures were approved by the

were challenged with Ang II (TLR4−/− Ang II, n = 7). The randomized

Wenzhou Medical University Animal Policy and Welfare Committee

animal division results in five treatment groups in total. STAT3 inhibi-

(Approval Document No. wydw2016‐0130), and all animals received

tor S3I‐201 was dissolved in 0.5% CMC‐Na buffer for these studies

humane care according to the National Institutes of Health (USA)

and orally administrated at 5 mg·kg−1 every other day in the 1‐month

guidelines. Animal studies are reported in compliance with the ARRIVE

schedule. Mice in WT Ctrl, WT Ang II, TLR4−/− Ctrl, and TLR4−/− Ang II

guidelines (Kilkenny et al., 2010; McGrath, Drummond, McLachlan,

groups were orally administrated with the vehicle (0.5% CMC‐Na

Kilkenny, & Wainwright, 2010) and with the recommendations made

buffer) in the same schedule. Previous studies have used S3I‐201 at

by the British Journal of Pharmacology. Eight‐week‐old male C57BL/6

10 mg·kg−1 for a short, 14‐day period of time in obstructive nephrop-

−/−

(stock #000664; RRID:IMSR_JAX:000664) and TLR4

mice (B6.

athy models (Matsui et al., 2017; Pang et al., 2010). Based on the

B10ScN‐Tlr4lps‐del/JthJ; Stock #007227; RRID:IMSR_JAX:007227)

expected level of fibrosis in Ang II‐challenged mice compared to

were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Ani-

obstructive kidney disease models, and the need for a longer term

mals were housed with a 12:12 hr light–dark cycle at a constant room

follow‐up, we treated the mice in this study with 5 mg·kg−1 every

temperature and fed a standard rodent diet. The animals were accli-

other day. This dose was empirically determined to reduce STAT3

matized to the laboratory for at least 2 weeks before initiating the

phosphorylation levels in mice.

studies. To develop the hypertensive model, mice were treated with

At the indicated time points, blood pressure was measured by tail‐

Ang II by subcutaneous injection (1.4 mg·kg−1·day−1 in phosphate

cuff using the telemetric blood pressure system (BP‐2010A, Softron

buffer, pH 7.2) for 1 month as described in our previous report (Skibba

Biotechnology). Measurements were performed during the day

et al., 2016). The control animals received the same volume of buffer

(1:00 p.m. to 5:00 p.m.) with previous 5 days of training. Blood pres-

(100 μl). All animal experiments were performed and analysed by

sure was measured each week, and 20 constant measurements were

blinded experimenters. Treatment groups were assigned in a random-

recorded at each point. After 1‐month treatment period, animals were

ized fashion. Each mouse was assigned a temporary random number

killed using sodium pentobarbital anaesthesia. At 6 hr before killing,

within the weight range. When mice were randomly divided in each

the spontaneous urine was collected using the following method: (a)

group, they were given their permanent numerical designation in the

the mouse was placed in a clean, dry, and empty cage and allowed

cages. For each group, a cage was selected randomly from the pool

to roam around; (b) the mouse is returned to its home cage and the

of all cages.

urine was aspirated using a pipette and transferred to a collection tube

Animal treatment (a): Adeno‐associated virus type/mutant 2

as soon as the mouse urinates. We collected urine, blood, and kidney

(AAV2) has been reported to produce robust expression in renal tissue

samples. Urine creatinine (Cr), albumin, and blood urea nitrogen (BUN)

(Qi et al., 2013). To knockdown STAT3 in mouse kidney, we injected

were detected using commercial kits (Nanjing Jiancheng Bioengineer-

AAV2 expressing STAT3 shRNA (Table S1; HanBio, BioTechnology

ing Institute). ELISA kits were used to determine IL‐6 (Thermo Fisher)

Co, Ltd., Shanghai, China) by tail vein 1 week before Ang II injection

and Ang II protein (Nanjing Jiancheng Bioengineering Institute) in kid-

(AAV‐shSTAT3). The control groups received the same volume of

ney tissue lysates.

AAV2 vehicle expressing negative control sequence (AAV‐NC). Ten‐
week‐old C57BL/6 mice (n = 28) were randomly allocated initially into
two larger groups (n = 14 per group). The mice in AAV‐shSTAT3 group

2.3

|

Human kidney samples

were further divided such that seven mice were randomized to receive
daily subcutaneous injections of Ang II and seven to receive an equal

Human tissues were obtained from the First Affiliated Hospital of

volume of vehicle daily. Similarly, the AAV‐NC control animals were

Wenzhou Medical University. The procedure was approved by the

randomized either to receive daily injections of Ang II (n = 7) or vehicle

Ethical Committee of First Affiliated Hospital of Wemzhou Medical

(n = 7), resulting in four treatment groups in total: (a) AAV2‐NC‐

University (Ethics Number: LCYJLS‐2018‐157) and was carried out

treated control mice that received PBS (AAV2‐NC group, n = 7);

in accordance with the Declaration of Helsinki. Archival kidney tissue

2630
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from five patients with hypertension and five individuals without

saturated aqueous solution of picric acid to evaluate type IV collagen

hypertension was examined. The tissue had been obtained at the time

deposition. To quantify the level of fibrosis, 10 non‐overlapping fields

of nephrectomy for conventional renal carcinoma, with kidney tissue

in each tissue (n = 7) were scored on a semiquantitative scale (<5%,

examined from regions of the kidney unaffected by tumour. The kid-

5–10%, 10–25%, 25–50%, 50–75%, and 75–100%), relative to total

ney biopsies were taken from roughly the same part of the kidney.

tissue area in the field.

Details of the patients are provided in Table S3. Sufficient frozen tis-

To detect phosphorylated STAT3 (p‐STAT3) in mouse kidneys,

sue was obtained to enable RNA isolation and qPCR, and protein

tissue sections were deparaffinized and hydrated. After performing

detection.

heat‐induced antigen retrieval in citrate buffer (pH 6), endogenous
peroxidase was blocked. Slides were then incubated with anti‐p‐

2.4

|

Western blot analysis and immunoprecipitation

The antibody‐based procedures used in this study comply with the
recommendations made by the British Journal of Pharmacology. Cell
and tissue homogenates were prepared. Protein samples were subjected to 8–12% SDS‐PAGE and transferred onto PVDF membrane
(Bio‐Rad Laboratory, Hercules, CA). Membranes were then probed
with specific primary and secondary antibodies. Antigen–antibody
complexes were visualized using enhanced chemiluminescence
reagents (Bio‐Rad).
For immunoprecipitation, cell extracts were prepared and incubated with anti‐TLR4 or anti‐JAK2 antibody for 1 hr. Proteins were
immunoprecipitated with protein G‐Sepharose beads at 4°C overnight. Samples were used for the detection of JAK2 or TLR4 as co‐

STAT3 (phospho‐Tyr705) antibody; Cell Signaling Technology, Danvers,
MA) overnight at 4°C. HRP‐conjugated secondary antibody and DAB
chromogen were used for detection. Sections were counterstained
with haematoxylin. p‐STAT3 in frozen human kidney tissues was
detected by immunofluorescence staining. Tissues were fixed in acetone and blocked in 5% BSA (Sigma‐Aldrich, St Louis, MO; Cat#
B2064). Fluorophore‐conjugated secondary antibodies were used,
and slides were counterstained with DAPI (Abcam, Cambridge, MA,
USA; Cat# ab104139).
To stain cultured cells, we fixed the cells in formalin and permeabilized by Triton. Primary p‐STAT3 antibody was applied overnight
at 4°C. Fluorophore‐conjugated secondary antibody was then applied
for 1 hr at room temperature. Cells were counterstained with DAPI. All
images were captured using a Nikon microscope (Nikon, Japan).

precipitated proteins. The density of the immunoreactive bands was
analysed using Image J software (NIH, Bethesda, MD; RRID:

2.7

|

Data and statistical analysis

SCR_003070).
The data and statistical analysis comply with the recommendations of

2.5 | Reverse transcription and real‐time
quantitative PCR

the British Journal of Pharmacology on experimental design and analysis
in pharmacology (Curtis et al., 2018). All experiments were randomized
and blinded. In all in vitro experiments, data represent five indepen-

Total RNA was isolated from cells or tissues using TRIzol (Invitrogen).

dent experiments and expressed as means ± SEM. The exact group

cDNA was synthesized from 1 μg total RNA with M‐MLV Reverse

size (n) for each experimental group/condition is provided and “n”

Transcriptase (Invitrogen) and random hexamer primers. Real‐time

refers to independent values, not replicates. Statistical analysis was

qPCR was carried out using the Eppendorf Real plex 4 instrument

performed with GraphPad Prism 6.0 software (San Diego, CA, USA;

(Eppendorf, Hamburg, Germany). Primers sequences are presented in

RRID:SCR_002798). We used one‐way ANOVA followed by

Table S4. The relative amount of each gene was normalized to the

Dunnett's post hoc test when comparing more than two groups of

amount of β‐actin. The ΔΔ‐Ct algorithm was used for RT‐qPCR

data and one‐way ANOVA, non‐parametric Kruskal–Wallis test,

analysis.

followed by Dunn's post hoc test when comparing multiple independent groups. P values of ˂.05 were considered to be statistically signif-

2.6

|

Histology and immunostaining

icant. Post‐tests were run only if F achieved P < .05 and there was no
significant variance inhomogeneity.

Kidney specimens from mice were fixed in 10% neutral‐buffered formalin and embedded in paraffin. Tissue sections were subjected to

2.8

|

Materials

haematoxylin–eosin staining and periodic acid‐Schiff (PAS) for routine
histological analysis. Mesangial matrix expansion was evaluated from

The suppliers of the antibodies used were as follows: antibodies to

the examination of PAS staining. For PAS scoring, semiquantitatively

phospho‐STAT3 (Tyr705), Cat. #9145 and Stat3, Cat. #9139 were from

on 30–50 glomeruli per kidney in each group (n = 7), using a scale from

Cell Signaling Technology: antibodies to phospho‐JAK2 (Tyr1007 + 1008)

0 to 4 score for description: 0 indicates no mesangial matrix expan-

Cat. #ab32101; JAK2, Cat. #ab108596; Lamin B, Cat. #ab16048;

sion, 1 for minimal, 2 for mild, 3 for moderate, and 4 for diffuse

TLR4, Cat. #ab22048; AT1 receptor, Cat. #ab18801; Collagen IV,

(Melhem, Craven, Liachenko, & DeRubertis, 2002; Susztak, Raff,

Cat. #ab34710; TGF‐β1. Cat. #ab92486; GAPDH, Cat. #ab8245; don-

Schiffer, & Bottinger, 2006). Paraffin sections were also stained with

key anti‐rabbit IgG H&L (Alexa Fluor® 647) Cat. #ab150075; rabbit

0.1% Sirius Red F3B (Solarbio Life Science, Beijing, China) and 1.3%

anti‐human IgG H&L (TRITC), Cat. #ab6756; goat anti‐mouse IgG

XU
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H&L (HRP) Cat. #ab6789 were from Abcam. Santa Cruz (Santa Cruz,

3
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RESULTS

CA) supplied the mouse anti‐rabbit IgG‐HRP, Cat. #sc2357. Other
compounds were supplied as follows: S32‐201, (Sigma‐Aldrich, Cat#
SML0330); human Ang II, (Aladdin, Shanghai, China; Cat# A107852);

3.1 | Increased STAT3 activation in kidneys is
associated with hypertension

protein phosphatase inhibitors (Solarbio, Cat#P1260) and PMSF
(Sangon Biotech, Cat# A100754). SC144 was supplied by Selleck

To investigate the role of STAT3 in hypertension‐associated kidney

Chemicals (Houston, TX)

injury, we examined archived renal biopsy specimens from normotensive and hypertensive human subjects. These samples had been
obtained at the time of nephrectomy for renal carcinoma, but only tis-

2.9

|

Nomenclature of targets and ligands

sues unaffected by tumour were analysed. We first stained the tissue
sections for p‐STAT3(Tyr705) as a proxy for STAT3 activation, because

Key protein targets and ligands in this article are hyperlinked to

phosphorylation at this residue is the main method of activating

corresponding entries in http://www.guidetopharmacology.org, the

STAT3 by the upstream JAK (Levy & Darnell, 2002). Our results

common portal for data from the IUPHAR/BPS Guide to PHARMA-

showed increased p‐STAT3 immunoreactivity in kidney tissues

COLOGY (Harding et al., 2018), and are permanently archived in

obtained from hypertensive subjects (Figure 1a), with no detectable

the Concise Guide to PHARMACOLOGY 2017/18 (Alexander,

staining in tissues from normotensive subjects. Lysates prepared from

Christopoulos et al., 2017; Alexander, Fabbro et al., 2017a,b;

frozen tissues confirmed increased levels of p‐STAT3 proteins found

Alexander, Kelly et al., 2017).

in the samples from hypertensive patients (Figure 1b), along with

FIGURE 1 Levels of STAT3 in human kidney tissues from hypertensive subjects. (a) Representative immunofluorescence staining images of
human kidney samples, with a quantification graph for p‐STAT3/STAT3 immunofluorescence. Kidney tissues unaffected by tumour from five
renal carcinoma patients without hypertension and five with hypertension were obtained and stained for the phosphorylated form of STAT3
(Tyr705) as well as total STAT3. Figure showing p‐STAT3 in red. Slides were counterstained with DAPI (blue). (Scale bar = 200 μm). (b)
Representative western blot analysis of phospho‐STAT3 in lysates prepared from human renal tissue, as well as the densitometric quantification
from five samples per group. STAT3 antibody detecting unphosphorylated forms was used as loading control. (c) Angiotensin II levels in human
kidney tissue lysates as measured by ELISA. Data were normalized to total amount of proteins in the lysates. Data shown are means ± SEM; n = 5.
*P < .05, significantly different from normotensive

2632
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increased levels of Ang II (Figure 1c). Although these results are

levels of kidney tissue Ang II were expected, as previous studies have

derived from a limited number of samples, the data do indicate a

demonstrated that Ang II infusion augmented levels of intrarenal

potential link between hypertension, Ang II level, and STAT3 activa-

angiotensinogen (Gonzalez‐Villalobos et al., 2008). Analysis of tissue

tion in human kidney tissues.

lysates showed that Ang II administration in mice increased the levels
of p‐STAT3 (Figure 2b). As expected, both STAT3 and p‐STAT3 levels

3.2
Inhibition of STAT3 activation preserves renal
function in mice challenged with Ang II
|

were markedly reduced in mice injected with AAV2‐STAT3 shRNA,
with or without Ang II challenge (Figure 2b). Furthermore, prevention
of STAT3 activation in kidney tissues was not associated with any

Recent studies have shown that administration of a JAK2 inhibitor

discernable changes in systolic blood pressure (Figure 2c). Importantly,

prevented the development of renal injury in a renal ischaemia/

blood pressure monitoring in mice validated the model of Ang

reperfusion model (Yang et al., 2008). Furthermore, blocking AT1 recep-

II‐induced hypertension.

tors or inhibiting JAK2 prevented the progression of proteinuria and

We next examined parameters of kidney damage in these mice.

hypertension in streptozotocin‐induced diabetic nephropathy (Banes

The data show that Ang II administration decreased body weights

et al., 2004). To test the role of STAT3 in hypertension‐associated kid-

but increased kidney tissue weights in the mice, after 1‐month injec-

ney damage, we challenged mice with Ang II through subcutaneous

tion (Figures S1 and 2d). This increase in kidney tissue weight was

administration. In this model, we inhibited STAT3 through injecting

not seen in mice in which STAT3 was knocked down. Similar results

AAV2 (Qi et al., 2013) expressing STAT3 shRNA. Ang II administration

were obtained when we examined urinary albumin : creatinine ratios

in mice was associated with increased levels of Ang II in kidney tissues

or levels of BUN (Figure 2e,f). These findings suggest that Ang II

(Figure 2a). No changes were detected in AAV2‐STAT3 shRNA injected

increases STAT3 activation and that STAT3 may mediate Ang II‐

mice compared to those treated with negative control AAV2. Increased

induced kidney dysfunction.

FIGURE 2 Knockdown of STAT3 protects against angiotensin II‐induced renal injury. STAT3 was inhibited in mice by injecting adeno‐associated
virus expressing STAT3 shRNA into 8‐week‐old C57BL/6 mice by tail vein. After 1 week, angiotensin II was administered by subcutaneous
injection at 1.4 mg·kg−1·day−1 for 1 month. (a) Angiotensin II protein levels in mouse kidney tissues as detected by ELISA (AAV2‐NC = negative
control shRNA expressing AAV; AAV2‐shSTAT3 = STAT3 shRNA expressing AAV. Data shown are means ± SEM; n = 7. *P < .05, significantly
different as indicated; ns = not significant. (b) Representative western blot analysis of p‐STAT3 in mouse kidneys. Total STAT3 and GAPDH were
used as controls. The graphs on the right show the summary data from western blots, as means ± SEM; n = 7. * P < .05, significantly different as
indicated; ns = not significant. (c) Systolic blood pressure in mice showing values at indicated time points. Data shown are means ± SEM; n = 7.
*P < .05, significantly different as indicated; ns = not significant. (d) Kidney tissue weights showing the effect of STAT3 knockdown. Ang II
administration increased kidney tissue weight, which was not seen in mice injected with STAT3 shRNA expressing AAV. Data shown as ratio of
kidney weight to body weight (means ± SEM; n = 7). *P < .05, significantly different as indicated; ns = not significant.. (e, f) Metabolic profile of
angiotensin II‐induced mice showing urine albumin to creatinine ratio (e), and serum urea nitrogen (f). Data shown are means ± SEM; n = 7.
*P < .05, significantly different as indicated; ns = not significant
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3.3 | STAT3 regulates Ang II‐induced fibrotic
responses in mouse kidneys
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by extracellular matrix (Yu, Noble, & Border, 2002), we stained kidney
sections with PAS to measure mesangial matrix expansion and Sirius
Red staining to highlight collagen deposition. The data show global

We next examined the kidney tissues of mice following STAT3 knock-

mesangial matrix expansion was observed in AAV2‐NC + Ang II group,

down. Histopathology showed that Ang II‐induced glomerular abnor-

while this change was attenuated in the AAV2‐shSTAT3 group

malities, primarily showing disarrayed glomerular tufts and mesangial

(Figure 3b,d). Also, there was significant fibrosis in kidney tissues of

proliferation (Figure 3a). These histological abnormalities were

mice challenged with Ang II, while only minimal staining was seen

reduced in mice with STAT3 knockdown. As the progress of kidney

around glomeruli in kidney tissues of mice with STAT3 silencing

disease is characterized by the loss of renal cells and their replacement

(Figure 3c,e). We know from previous studies that Ang II modulates

FIGURE 3 Knockdown of STAT3 prevents renal fibrosis in mice with angiotensin II‐induced hypertension. (a) Representative haematoxylin and
eosin (H&E) staining of kidney tissues harvested from mice with hypertension induced by angiotensin II (Ang II). The lower panel showed the
zoomed in images of glomerulus from each group (upper scale bar = 200 μm; lower scale bar = 10 μm). (b) Representative images of PAS staining
(scale bar = 10 μm). (c) Representative images of kidney tissues showing Sirius Red staining (scale bar = 200 μm). (d) Quantification of mesangial
matrix score in panel b. Data shown are means ± SEM; n = 7. *P < .05, significantly different as indicated; ns = not significant. (e) Quantification of
fibrotic areas in panel c. Data shown as percent total area. Data shown are means ± SEM; n = 7. *P < .05, significantly different as indicated;
ns = not significant.. (f) Western blot analysis of TGF‐β and type I and IV collagen in kidney tissues from mice. GAPDH was used as loading control
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fibrosis by up‐regulating the expression of TGF‐β (Fogo, 2001). In fact,

1997), also showed that JAK2 was activated at 5–30 min after Ang

up‐regulation of TGF‐β1 has been demonstrated in nearly every type

II stimulation (Figure 4c). These results showed that JAK2 may be

of fibrotic renal disease in animals and in humans (Bottinger & Bitzer,

involved in Ang II‐induced STAT3 activation in kidney epithelial cells.

2002; Zeisberg, Strutz, & Muller, 2001). Hence, we determined the

An interesting finding in our study was the rapid activation of

levels of TGF‐β in kidney tissues of these mice. As shown in

STAT3 by Ang II in cultured kidney epithelial cells. Previous studies

Figure 3f, Ang II‐induced TGF‐β and collagen I/collagen IV levels in

have shown that Ang II induces rapid phosphorylation of STAT1 and

kidney tissues of mice with intact STAT3 but not in mice in which

STAT2 with delayed phosphorylation of STAT3 in cardiomyocytes.

STAT3 had been knocked down.

The delayed activation of STAT3 in cardiac cells is believed to be
due to enhanced synthesis and release of IL‐6 (Sano et al., 2000).
Therefore, we measured IL‐6 production and release by kidney epithe-

3.4
Rapid activation of STAT3 in renal tubular cells
is mediated through TLR4, independent of IL‐6/gp130
and angiotensin AT1 receptors
|

lial cells exposed to Ang II for 0–120 min. Surprisingly, no changes
were noted in IL‐6 levels (Figure 4d). At least at the early phase of
Ang II stimulation, Ang II did not seem to involve IL‐6‐mediated STAT3
activation. To confirm this, we inhibited IL‐6 signalling by treating

To tease out the mechanisms of STAT3 activation by Ang II in kidneys,

NRK‐52E cells with the IL‐6/gp130 inhibitor SC144. Our results con-

we utilized kidney NRK‐52E epithelial cells. We exposed the cells to

firm that pretreatment with SC144 did not inhibit Ang II‐induced

Ang II for different periods and examined the levels of p‐STAT3. Our

STAT3 phosphorylation in kidney epithelial cells, indicating that Ang

results show rapid STAT3 phosphorylation in response to Ang II and

II‐induced rapid STAT3 activation was not mediated by IL‐6/gp130.

this was maintained for 90 min in kidney epithelial cells (Figure 4a).

To identify the signalling mechanism engaged by Ang II to cause

We confirmed the phosphorylation of STAT3 by staining NRK‐52E

STAT3 activation, we performed a series of candidate protein knock-

cells following Ang II stimulation. The results show Ang II increased

downs. We transfected NRK‐52E cells with siRNA targeting AT1

immunoreactivity in cells (Figure 4b). Analysis of JAK2, which has been

receptors and another for JAK2. Silencing of the AT1 receptors failed

shown to activate STAT3 in kidney mesangial cells (Marrero, Banes‐

to inhibit either JAK2 or STAT3 phosphorylation in response to Ang II

Berceli, Stern, & Eaton, 2006) and vascular cells (Marrero et al.,

(Figure 5a). As expected from our results described above, JAK2

FIGURE 4 Angiotensin II activates STAT3
phosphorylation in kidney epithelial cells,
independent on IL‐6 pathway. (a) Western
blot analysis of p‐STAT3 levels in rat kidney
epithelial line NRK‐52E following exposure to
angiotensin II (Ang II). Cells were exposed to
1‐μM angiotensin II for the indicated time
points and p‐STAT3 levels in cell lysates were
probed. Total STAT3 and GAPDH were used
as loading control. (b) Representative
immunofluorescence images showing levels
and localization of p‐STAT3 (red) in NRK‐52E.
Cells were exposed to 1‐μM angiotensin II for
the indicated time points. Cells were
counterstained with DAPI (blue; scale
bar = 20 μm). (c) Western blot analysis of
phosphorylated JAK2 (Tyr1007 + 1008) levels in
NRK‐52E cells following exposure to
angiotensin II. Cells were treated as in panel a.
Total JAK2 and GAPDH were used as loading
control. (d) Levels of IL‐6 in NRK‐52E
conditioned culture media as determined by
ELISA. Cells were exposed to angiotensin II
and IL‐6 levels in media were measured at
indicated times (ns = not significant compared
to 0 min). (e) Effect of inhibiting IL‐6/gp130
by SC144 on angiotensin II‐induced STAT3
phosphorylation. NRK‐52E were pretreated
with SC144 for 1 hr before exposure to 1‐μM
angiotensin II STAT3 phosphorylation was
determined by immunoblotting. Total STAT3
and GAPDH were used as controls
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phosphorylation

treated NRK‐52E cells with increasing concentrations of S3I‐201

(Figure 5b). We then silenced TLR4 and probed for STAT3 activation.

before challenging the cells with Ang II. S3I‐201 reduced the phos-

Our results show that TLR4 deficiency reduces both JAK2 and STAT3

phorylation of STAT3 without altering the levels of STAT3 protein

phosphorylation (Figure 5c). This result supported our hypothesis of

(Figure S2a, b). Analysis of nuclear fractions also revealed that

silencing

prevented

Ang

II‐induced

STAT3

the involvement of TLR4 in Ang II‐induced STAT3 activation. Co‐

S3I‐201 reduced Ang II‐induced STAT3 activation and nuclear translo-

immunoprecipitation studies indeed showed a rapid protein–protein

cation (Figure S2b,c). Furthermore, S3I‐201 did not alter JAK2 levels

interaction between TLR4 and JAK2 in response to Ang II stimulation

(Figure S2a,b), consistent with our gene silencing data (Figure 5e).

of NRK‐52E cells (Figure 5d). We next performed gene knockdown for

Using the lowest concentration from these studies, we show that inhi-

STAT3 to determine whether there exists a feedback system regulat-

bition of STAT3 by S3I‐201 at 2.5 μM prevents Ang II‐induced colla-

ing JAK2 and/or TLR4 in kidney epithelial cells. As shown in

gen and TGF‐β protein levels (Figure 6b). These findings show that

Figure 5e, no alterations in the levels of p‐JAK2 and TLR4 were

Ang II‐mediated STAT3 activation is involved in fibrotic responses in

observed upon STAT3 knockdown. Collectively, these findings show

kidney cells.

that Ang II causes rapid STAT3 activation in kidney epithelial cells
through engaging TLR4‐JAK2, independent of AT1 receptors.

3.5 | Ang II‐induced STAT3 mediates fibrotic
responses in kidney epithelial cells

3.6 | TLR4 deficiency and STAT3 inhibition protects
kidneys from Ang II‐induced unregulated remodelling
and fibrosis
Our last objective was to provide empirical evidence linking Ang

We next determined the functional consequence of Ang II‐induced

II‐TLR4‐STAT3 to renal fibrosis. To achieve this goal, we challenged

STAT3 activation in kidney epithelial cells. We silenced STAT3 in

TLR4‐deficient mice with Ang II. In addition, we inhibited STAT3 in

NRK‐52E cells and examined for induction of fibrotic proteins in

wild‐type mice using oral administration of S3I‐201 to bolster the

response to Ang II. Transfection of cells with siRNA against STAT3,

results obtained using AAV2‐STAT3 shRNA. Ang II increased systolic

which significantly reduced STAT3 proteins (Figure 5e), showed no

blood pressure in mice (Figure S3). Neither TLR4 deficiency nor STAT3

induction of collagen or TGF‐β in response to Ang II (Figure 6a). To

inhibition in wild‐type mice prevented Ang II‐mediated increased

confirm these results, we utilized a pharmacological inhibitor of

blood pressure.

STAT3, S3I‐201. S3I‐201 specifically prevents STAT3 phosphorylation

Administration of Ang II increased kidney Ang II levels in both wild‐

and subsequent complex formation, and STAT3‐DNA binding activity

type and TLR‐deficient mice (Figure 7a). The STAT3 inhibitor or TLR4

(Siddiquee et al., 2007). To validate this inhibitor in our system, we

deficiency had no effect on kidney Ang II levels. Analysis of tissue

FIGURE 5 Angiotensin II phosphorylates STAT3 through toll‐like receptor4 (TLR4)‐JAK2 interaction. (a–c) The effect of knocking down AT1
receptors (a), JAK2 (b), and TLR4 (c) on JAK and STAT3 phosphorylation induced by angiotensin II (Ang II). NRK‐52E epithelial cells were
transfected with siRNAs which target candidate signalling proteins involved in STAT3 activation for 6 hr. After 6‐hr transfection, cells were
exposed to 1‐μM angiotensin II for 5 min and then p‐JAK/JAK was probed by immunoblotting; or cells were exposed to 1‐μM angiotensin II for
60 min and then p‐STAT3/STAT3 and AT1 receptors (or TLR4) were probed by immunoblotting. (d) Lysates prepared from NRK‐52E cells
stimulated with 1‐μM angiotensin II for indicated time points were subjected to immunoprecipitation with TLR4 or JAK2 antibody (IP) and
subsequent detection of JAK2 or TLR4 (IB) respectively. (e) NRK‐52E epithelial cells were transfected with siRNA which targets STAT3 for 6 hr.
After 6‐hr transfection, cells were exposed to 1‐μM angiotensin II for 5 min and then p‐JAK/JAK, STAT3, and TLR4 proteins were probed by
immunoblotting. All blots are representative from five independent experiments
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FIGURE 6 Inhibition of STAT3 prevents
angiotensin II‐induced fibrotic responses in
kidney epithelial cells. (a) NRK‐52E cells were
transfected with siRNA targeting STAT3 or
negative control siRNA. Cells were then
exposed to 1‐μM angiotensin II (Ang II) for
24 hr. Lysates were probed for the levels of
type IV collagen and TGF‐β. GAPDH was used
as loading control. Blots are representative
from five independent experiments. (b) Effect
of STAT3 inhibitor S3I‐201 on angiotensin II‐
induced fibrogenic protein levels in NRK‐52E
cells. Cells were pretreated with S3I‐201 for
1 hr before being exposed to angiotensin II for
24 hr. Type IV collagen and TGF‐β levels were
determined by immunoblotting. GAPDH was
used as loading control. All blots are
representative from five independent
experiments

lysates clearly showed increased p‐STAT3 and JAK2 in wild‐type mice

STAT3 in response to Ang II and were protected against Ang II‐

upon Ang II administration (Figure 7b). As expected, S3I‐201 treat-

induced kidney dysfunction.

ment of mice reduced p‐STAT3 but showed no effect on JAK2 phos-

Among the various regulatory systems that affect blood pressure,

phorylation levels. TLR4‐deficient mice failed to increase JAK2 and

the RAS plays a significant role. A large body of experimental evidence

STAT3 phosphorylation in response to Ang II challenge. We confirmed

shows that Ang II is able to induce the pathological hallmarks of hyper-

STAT3 phosphorylation by Ang II by staining kidney tissues from these

tensive kidney disease. Kidneys have their own intact RAS and

mice. Ang II‐induced p‐STAT3 immunoreactivity was reduced by S3I‐

intrarenal angiotensinogen is produced in renal proximal tubular cells

201 treatment, and not seen in TLR4‐deificient mice (Figure 7c).

(Kobori, Harrison‐Bernard, & Navar, 2001), compatible with significant

STAT3 inhibition by S3I‐201 and TLR‐deficiency protected mice

role in hypertensive kidney disease. Ang II administration has also

from Ang II‐mediated kidney dysfunction as observed by urinary albu-

been reported to increase intrarenal angiotensinogen expression

min to creatinine ratios and BUN (Figure 7d,e). Histopathology also

(Gonzalez‐Villalobos et al., 2008). This intrarenal Ang II facilitates the

showed reduced structural abnormalities and fibrosis upon STAT3

progression of hypertension and renal injury (Gonzalez‐Villalobos

inhibition and TLR‐deficiency (Figure 8a–e). Finally, western blot anal-

et al., 2009). Our analyses show that chronic Ang II administration in

ysis showed that TLR4 knockout mice do not exhibit Ang II‐mediated

mice results in increased Ang II protein levels in kidney tissues of mice.

increases in collagen and TGF‐β levels (Figure 8f). STAT3 inhibitor S3I‐

Recently, Marrero and colleagues showed that Ang II induces rapid

201 also suppressed collagen I, IV, and TGF‐β levels. Interestingly, the

phosphorylation of JAK2 in aortic smooth muscle cells (Bottinger &

inhibitory effect on collagen by S3I‐201 was quite robust compared to

Bitzer, 2002). Although these important studies resulted from cardio-

TGF‐β. This may be due to different cell types or signalling pathways

vascular cells, Ang II‐induced activation of the JAK–STAT pathway

contributing to Ang II‐mediated TGF‐β induction. Taken together,

has been demonstrated in renal proximal tubular cells and mesangial

our studies show that Ang II activates STAT3 through TLR4, and

cells (Marrero et al., 2006; Zhang, Guo, Moini, & Ingelfinger, 2004).

increased STAT3 activity causes renal fibrosis and dysfunction.

These later studies implicated the JAK/STAT pathway in hypertensive
kidney disease. In the present study, analysis of human kidney samples
from hypertensive and normotensive patients showed increased levels
of both Ang II and STAT3 phosphorylation. Although we are unable to

4

|

DISCUSSION

confirm the cellular source of Ang II and activated STAT3 in human
kidney tissues, our results do implicate these two proteins in hyper-

The key findings of our study include the discovery that Ang II acti-

tensive kidney disease. It is interesting to note that p‐STAT3 was ele-

vates STAT3 in kidney epithelial cells through engaging TLR4 and

vated in kidney samples from hypertensive subjects compared with

JAK2, independent of IL‐6/gp130 and AT1 receptors. Ang II‐mediated

normotensive patients, despite the fact that these patients were youn-

STAT3 activation in kidney epithelial cells increased the expression of

ger (mean 39.8 years for hypertensive group compared to 63.2 years

collagen and TGF‐β. Chronic Ang II challenge increased fibrotic pro-

for normotensive group). Another limitation is that the numbers

teins and resulted in renal dysfunction in mice. As observed in our

in two groups were too small to be compared with each other. Previ-

in vitro studies, inhibition of STAT3 activation, by a low MW inhibitor,

ous studies also showed increasing levels of STAT3 with increasing

normalized structural and functional alterations in mice caused by Ang

age in epithelial compartments of the renal cortex (O'Brown, Van

II. Finally, we showed that mice deficient in TLR4 did not activate

Nostrand, Higgins, & Kim, 2015). Further, STAT3 knockdown by
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FIGURE 7 TLR4 knockout mice are protected against angiotensin II‐induced STAT3 activation and renal dysfunction. Angiotensin II (Ang II) was
administered to 8‐week‐old TLR4−/− and wild‐type (WT) littermates by subcutaneous injection for 1 month. One experimental group of WT mice
receiving Ang II were treated with STAT3 inhibitor S3I‐201. (a) Angiotensin II levels in mouse kidney tissues as detected by ELISA. Data shown are
means ± SEM; n = 7. *P < .05, significantly different as indicated; ns = not significant. (b) Western blot analysis of TLR4 and phosphorylated JAK2
and STAT3 in kidney tissues of mice challenged with angiotensin II . Total JAK2, STAT3, and GAPDH were used as internal controls.
Representative blot is shown from n = 7 per group. (c) Representative immunohistochemical staining for p‐STAT3 (brown) in kidney tissue
harvested from WT and TLR4‐deificent mice. Tissues were counterstained with haematoxylin (blue; scale bar = 400 μm). (d–f) Kidney/body
weight ratio (d), levels of urine albumin to creatinine ratio (e), and serum BUN (f) were determined in each group. Data shown are means ± SEM;
n = 7 per group. *P < .05, significantly different as indicated; ns = not significant
AAV2 significantly attenuated Ang II‐induced renal fibrosis in mice.

knockdown and pharmacological inhibition of STAT3 protected kidney

We noted that the AAV2 method may cause STAT3 down‐regulation

function and reduced fibrosis in mice challenged with Ang II. These

in other tissues. Whether STAT3 inhibition in other tissues (e.g., in

results show that STAT3 inhibition provides significant protection

liver) plays a role in renal protection was not investigated in this study.

against Ang II‐induced extracellular matrix production and fibrosis,

STAT3 inhibition has been reported to protect renal injuries. For

both in an acute setting (cell culture studies) and chronic setting

example, STAT3 inhibition has been shown to ameliorate damage

(mouse studies). In the cell cultures, cells were challenged with Ang

induced by unilateral ureteral obstruction (Pang et al., 2010),

II for a short time period. These challenged cells exhibited rapid but

ischaemia/reperfusion (Arany, Megyesi, Nelkin, & Safirstein, 2006;

transient increase in p‐STAT3. Inhibition of STAT3 in this setting

Neria et al., 2009), oxidative stress (Neria et al., 2009), and diabetes

reduced the expression of collagen and TGF‐β. Although, continuous

(Banes et al., 2004). Very recently, a STAT1/3/5 inhibitor,

challenge of mice with Ang II may result in a long‐term situation of

nifuroxazide, was shown to inhibit diabetes‐induced kidney fibrosis

STAT3 activation, STAT3 blockade in mice also lead to the similar

(Said, Zaitone, Eldosoky, & Elsherbiny, 2018). In our kidney epithelial

result: inhibition of fibrosis in kidneys. These findings warrant further

cell cultures, we showed that inhibiting STAT3 reduced Ang II‐

studies on S3I‐201 to determine whether this inhibitor has clinical util-

mediated expression of collagen and TGF‐β. In vivo, both gene

ity in treating hypertensive kidney disease.
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FIGURE 8 TLR4‐deficiency and STAT3 inhibition protects mice from angiotensin II‐induced renal fibrosis. (a) Representative haematoxylin and
eosin (H&E) stained kidney tissues from mice challenged with Ang II. The lower panel showed the zoomed in images of glomerulus from each
group (upper scale bar = 200 μm; lower scale bar = 10 μm). (b) Representative images of PAS staining showing mesangial expansion in the
glomeruli (scale bar = 10 μm). (c) Representative images of kidney tissues showing Sirius Red staining for types I, III, and V collagen. (d) Mesangial
matrix expansion score in panel b. Data shown as mean ± SEM; n = 7. *P < .05, significantly different as indicated; ns = not significant. (e)
Quantification of fibrotic areas in panel c. Data (means ± SEM) are shown as percent total area; n = 7. *P < .05, significantly different as indicated;
ns = not significant. (f) Western blot analysis of type I and IV collagen and TGF‐β in lysates prepared from kidney tissues of mice. GAPDH was used
as loading control. Representative blot is shown from n = 7 per group

We found that Ang II activated the JAK/STAT pathway through

TLR4 (Han et al., 2017). MD2 knockout mice are also protected

TLR4. In NRK‐52E cells, Ang II causes rapid STAT3 activation via

against Ang II‐mediated renal fibrosis and dysfunction (Xu et al.,

inducing TLR4 and JAK2 interaction, independent of AT1 receptors.

2017). In the delayed phase, continuous cell damage and oxidative

When TLR4 was knocked down in kidney epithelial cells, Ang II failed

stress induced by Ang II or hypertension generate the release of many

to activate JAK2 and STAT3. TLR4 knockout mice were also found to

potential danger signals which may be recognized by, and activate,

be protected against Ang II‐mediated JAK2 and STAT3 phosphoryla-

the TLR4.

tion. These findings suggest that TLR4 plays a significant role in

One of the limitations in this work is that we are unable to confirm

Ang II responsiveness. Previously, it was reported that TLR4 mutant

which cells are responsible for Ang II and STAT3 phosphorylation in

mice are protected from renal fibrosis in a partial nephrectomy with

mouse kidney tissues and human biopsy tissues. We performed the

Ang II infusion model (Souza et al., 2015). Others have shown that

mechanistic studies only in cultures of kidney epithelial cells. Although

decreased renal fibrosis in TLR4‐deficient mice upon unilateral

the NRK‐52E cells have some advantages mentioned above, we fully

ureteral obstruction (Braga et al., 2012). Our previous studies showed

aware that analysis of other kidney cell types is important. We antici-

that Ang II rapidly binds to a co‐receptor of TLR4, MD2 protein,

pate that other cell types in kidney tissues including mesangial cells

which suggests that Ang II, at least in early state, may directly activate

and podocytes may also utilize this signalling pathway. However, this
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of Ang II‐induced renal fibrosis has been associated with a reduction
of the epithelial‐to‐mesenchymal transition (He et al., 2018; Hu
et al., 2018; Wang et al., 2018). Such experiments are important to
better understand how STAT3 mediates epithelial loss and phenotype
change, as well tubular atrophy.
In conclusion, our study has uncovered potentially important
mechanisms underlying Ang II‐induced renal dysfunction. Our finding
that Ang II activates STAT3 in kidney epithelial cells through engaging
TLR4 and JAK2, independent of IL‐6/gp130 and AT1 receptors is significant. A unique interplay between Ang II, hypertension, and TLR4 is
emerging from recent studies. We showed that TLR4 deficiency does
not regulate hypertension, but hypertension‐associated changes may
regulate TLR4 to activate STAT3. We also demonstrated that Ang
II‐mediated STAT3 activation in kidney epithelial cells is important
for the induction of TGF‐β and collagen IV, two key drivers of fibrosis.
Inhibiting STAT3 by S3I‐201 normalized Ang II‐induced structural and
functional alterations in kidney tissues of mice, indicating a transla-
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